CCN5/WISP2 Protein Shows Dual Role in Preventing Age-Related Muscle Loss
Background
Sarcopenia, the progressive loss of muscle mass and function, is a debilitating condition affecting millions of older adults, leading to reduced quality of life and increased mortality. While various factors contribute to muscle atrophy, the precise molecular mechanisms governing muscle maintenance and regeneration are not fully elucidated. This study aimed to investigate the dual roles of CCN5/WISP2, a secreted protein, in both the cytosol and secretome for maintaining muscle homeostasis and preventing sarcopenia.
Results
The study revealed that CCN5/WISP2 plays a significant role in muscle health. In vitro, CCN5/WISP2 treatment increased C2C12 myoblast proliferation by 35% and enhanced differentiation markers by 2.8-fold. In aged wild-type mice, CCN5/WISP2 administration led to a 12% increase in quadriceps muscle mass compared to vehicle controls (p<0.01), and grip strength improved by 25% (p<0.001). Furthermore, muscle fiber cross-sectional area was 18% larger in treated mice. The most striking finding was that CCN5/WISP2 treatment significantly reduced the expression of atrophy-related genes (e.g., MuRF1, atrogin-1) by 40-50% while increasing anabolic pathways, demonstrating its potent anti-atrophic effects. CCN5/WISP2 knockout mice exhibited accelerated sarcopenia, with 20% lower muscle mass and 30% reduced grip strength compared to wild-type littermates by 18 months of age.
Why It Matters
This research highlights CCN5/WISP2 as a critical regulator of muscle homeostasis, acting both intracellularly and as a secreted factor to combat muscle wasting. The findings suggest that targeting CCN5/WISP2 pathways could offer a novel therapeutic strategy for sarcopenia and other muscle degenerative diseases. This discovery could pave the way for developing new drugs or interventions to prevent and treat age-related muscle loss, significantly improving quality of life for an aging population. Future research should focus on validating these findings in larger animal models and exploring its safety and efficacy in human clinical trials (Phase I/II).